The 2018 Impact Factors Have Been Announced!
Cligosiban Trial Results Encouraging for Men with Premature Ejaculation
We are proud to announce that the 2018 Impact Factor for The Journal of Sexual Medicine has increased from 3.34 (2017) to 3.65 (2018).
The journal is now ranked #1 among all sexual medicine journals and #14 out of a total of 80 journals in the urology/nephrology category.
Additionally, the 2018 impact factor for Sexual Medicine - Open Access is 1.44 similar to that of 2017 (1.46).
Many thanks to everyone who contributed to this success!
A selective oxytocin receptor antagonist called cligosiban is safe and well-tolerated in healthy men, according to two recent studies in the Journal of Sexual Medicine.
The drug is being developed for the treatment of premature ejaculation.
Researchers investigated the safety and tolerability of single and multiple oral doses of cligosiban in amounts ranging from 0.3 mg to 2,400 mg.
They assessed blood and urine samples from each man and cerebrospinal fluid from one subgroup of men.
More details on the study, including the researchers' thoughts on next steps, are available here.